Engineering CAR T-cell sharpshooters
Singapore, April 1 -- Approved CAR T-cell therapies have shown remarkable results in patients with certain types of blood cancers. However, further innovations are needed before the technology can reach its full potential. In principle, CAR T-cell therapies work because they are engineered with a chimeric antigen receptor (CAR) that is designed to recognise a cancer antigen expressed on the surface of that patient's cancer cells. When the CAR T-cell therapy is administered to the patient, these CAR T-cells coordinate a targeted immune response against the patient's cancer.
Ideally, the antigen for a traditional CAR T-cell (or a T-cell) would be universally and homogeneously expressed on cancer cells, but never expressed on healthy cells....
Click here to read full article from source
To read the full article or to get the complete feed from this publication, please
Contact Us.